v3.26.1
Segment Information - Schedule of Reportable Segment and the Significant Expenses, Including Consolidated Net Income (Loss) (Details) - Reportable Segment [Member] - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development expenses:        
General and administrative expenses $ 5,349 $ 5,139 $ 10,466 $ 9,474
Stock-based compensation expense 1,384 903 2,746 1,736
Income (loss) from operations (23,324) (16,586) (42,953) (30,710)
Other income (expense), net 1,656 1,626 3,503 3,836
Net Income (Loss) (21,668) (14,960) (39,450) (26,874)
Adjustments and reconciling items
Net income (loss) (21,668) (14,960) (39,450) (26,874)
TARA-002 in NMIBC [Member]        
Research and development expenses:        
Research and development expenses 6,848 4,898 12,686 8,455
TARA-002 in LMs [Member]        
Research and development expenses:        
Research and development expenses 852 477 1,660 1,027
IV Choline Chloride [Member]        
Research and development expenses:        
Research and development expenses 2,726 1,852 4,946 4,367
Other research and development [Member]        
Research and development expenses:        
Research and development expenses $ 6,165 $ 3,317 $ 10,449 $ 5,651